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Abstract. Transforming  growth factor-13  (TGFfl)  is a 
regulator of cellular proliferation  which can alter the 
proteolytic activity of cultured  cells by enhancing  the 
secretion of endothelial  type plasminogen  activator in- 
hibitor and  affecting the secretion of plasminogen  acti- 
vators (PAs) in cultured  fibroblastic cells.  We used the 
TGF~responsive  malignant  human  lung adenocarci- 
noma cell line A549 to study the relationships  be- 
tween the known TGFI3-induced  growth inhibition  and 
the effects of TGFI3  on the secretion of PA activity by 
A549 cells.  PA activity was quantitated  by caseinolysis 
assays, and characterized  by urokinase  mRNA analy- 
sis,  immunoprecipitation,  and zymography  assays.  PA- 
inhibitor  production  was observed in autoradiograms  of 
SDS-polyacrylamide  gels and reverse zymography  as- 
says. It was found that  TGF~I  enhanced  the production 
of PA activity by these cells,  in accordance with an 
enhancement  of urokinase  mRNA levels.  A  concomi- 
tant  stimulation  of type  1 PA-inhibitor  production  was 
also observed in A549 cells in response to TGFI3.  In 
contrast to the observations of A549 cells,  TGFI3 
caused a  decrease in the expression of both urokinase 
and the tissue-type PA mRNA in human embryonic 
WI-38 lung fibroblasts indicating  opposite regulation 
of the expression of PAs in these cells.  The  results 
suggest that TGFI3  may play a  role in the regulation  of 
the invasive,  proteolytically active phenotype of certain 
lung carcinoma  cells. 
M 
ALIGNANT transformation of cultured cells is often 
associated with the production of specific growth 
factors (see  10,  16, 23,  34),  some of which have 
been termed  transforming  growth  factors because of their 
ability  to  induce  anchorage-independent  growth  in  non- 
malignant  cells  (34,  43).  Transforming  growth  factor-13 
(TGFfl) l is mainly responsible for the induction of anchor- 
age-independent  growth  in  fibroblastic  cells,  either  alone 
(32)  or  in  combination  with  epidermal  growth  factor  or 
TGFet (43).  TGFI] acts presumably as a mitogen for fibro- 
blastic cells grown in adherent cultures by inducing the ex- 
pression of the c-sis protooncogene (30).  It appears,  how- 
ever,  to have a  dual  role in the regulation  of cell growth: 
while being stimulatory for cells of mesenchymal origin,  it 
is a potent growth inhibitor for cultured epithelial cells (35, 
44). The mechanism of this inhibitory activity of TGFI3 is 
unclear at present. 
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1. Abbreviations  used in this paper: PA, plasminogen activator;  PAl, plas- 
minogen activator inhibitor; u-PA, endothelial-type plasminogen activator 
inhibitor; TGFI3, transforming growth  factor-13. 
Plasminogen activators (PAs) are the major mediators of 
pericellular proteolysis. Enhanced proteolytic activity is fre- 
quently  observed  in  fibroblastic  cells  transformed  with 
viruses or chemicals,  as well as in cultured tumor cells (9, 
41, 46). Normal cells can evidently regulate the synthesis of 
plasminogen activators (18) whereas in cancer cell cultures 
elevated levels (see 46) and lack of response to growth factors 
(52) are frequently observed. At least two types of PAs exist 
in tissues: the urokinase- and tissue-type plasminogen acti- 
vators (u-PA and t-PA,  respectively), u-PA has specific cell 
surface  receptors  (50,  51,  56)  and  recently  an  autocrine 
model was proposed depicting features in the regulation of 
cell migration  (51). 
Several cell lines in culture also produce PA inhibitors (6, 
46). Three well-defined, immunologically different types ex- 
ist:  protease  nexin  I  (48,  49),  endothelial-type  (55)  and 
placental-type (3) PA inhibitors  (PAI-1 and PAI-2,  respec- 
tively). The secretion of PA inhibitors as well as PAs from 
cells  can  be affected by mitogens,  corticoids,  and  tumor 
promoters (1, 8, 12,  18, 27, 29, 52; see 9, 46). Simultaneous 
secretion of both PAs and the inhibitors complicates the anal- 
yses since it is necessary to use test systems which allow dis- 
crimination between total and inhibitor-modulated PA activ- 
ity  (see  6,  46).  We  have  recently  shown  that  TGFI3  can 
modulate the proteolytic activity of cultured dermal  fibro- 
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PA inhibitors. A dominant feature in the action of TGFI~ is 
the induction of PAI-1 (26, 27). 
To determine whether PA activity is affected in an epithe- 
lial lung cell line that is sensitive to TGFI~ growth inhibition, 
we studied the effects of TGFI~ on the proteolytic activity of 
A549  cells  in  culture  and  compared  the  responses  with 
fibroblastic lung cells. We find that TGFI3 enhances the level 
of u-PA mRNA in A549 cells while decreasing it in WI-38 
human  lung  fibroblasts.  In  accordance with  our previous 
observations (26, 27), enhanced secretion of the type-1 plas- 
minogen activator inhibitor was also seen. However, quanti- 
fication of the net PA activities by caseinolysis assays demon- 
strated that TGFI~ enhanced the overall proteolytic activity 
of A549 cells. We report here that TGFI~ regulates two of the 
three components of the u-PA system in human A549 cells 
controlling the synthesis and activity of u-PA and secretion 
of PAI-1. 
Materials and Methods 
Reagents 
Human  urokinase  was  purchased  from  Calbiochem Behring Corp.  (La 
Jolla, CA), aprotinin from Sigma Chemical Co. (St. Louis, MO). TGFI3 was 
purified from outdated human platelets as described (35).  The TGFI3 was 
shown to be homogeneous by silver staining of SDS-PAGE under reducing 
and nonreducing conditions and autoradiography of gels of reduced and 
nonreduced  1251-TGF~. Its  growth  stimulatory  and  inhibitory properties 
were demonstrated using AKR-2B and A549 cells as described. TGF~ in- 
hibits efficiently the soft agar growth of A549 cells at a concentration of 0.5 
ng/ml, and totally prevents it at 5 ng/ml (35,  44). 
Cell Cultures 
Human embryonic lung WI-38 fibroblasts (CCL-75;  American Type Cul- 
ture Collection, Rockville, MD), human HT-1080 sarcoma cells (CCL-121; 
American Type Culture Collection), and A549 lung adenocarcinoma cells 
(CCL-185;  American Type Culture Collection) were cultivated in medium 
199 containing 10% heat-inactivated FCS (Gibco, Chagrin Falls, OH),  100 
IU/ml penicillin, and 50  ~tg/ml streptomycin at 37~  in a  humidified at- 
mosphere containing 5%  CO2. 
Stimulation by Growth Factors 
Cells were seeded at a density of 3.0  x  104 per Linhro well (16 mm diam; 
Flow Laboratories, Inc., McLean, VA). Upon confluency the medium was 
replaced with serum-free medium 199 and incubated at 37~  for an addi- 
tional 6 h  to remove most serum proteins. The medium was replaced by 
fresh medium 199 and the growth factors were added as indicated. The cul- 
tures were then incubated at 37~  for 2-48 h and labeled with [35S]methio- 
nine where indicated. The medium and the cells were collected and ana- 
lyzed as described. 
Radioactive Labeling 
Confluent cultures were washed and incubated in serum-free medium 199 
for 6 h. The medium was changed and the cultures were labeled with 50 
I.tCi/ml [35Slmethionine  (1,390 Ci/mmol; Amersham International, Amer- 
sham, UK) in the presence of  TGFI3, and aprotinin where indicated, at 37~ 
for 4-24 h. The medium was collected and clarified by centrifugation (600 
g, 10 min). 1-ml  aliquots of the supernatant were then incubated with 50-~tl 
aliquots (50% of suspension in PBS;  10 mM sodium phosphate, 140 mM 
sodium chloride, pH 7.4) of concanavalin A-Sepharose (Con A-Sepharose; 
Pharmacia,  Uppsala,  Sweden) at 22~  in a  rotary shaker for 2  h.  Con 
A-Sepharose is known to bind PAI-1 efficiently (1, 26). The Sepharose parti- 
cles were washed four times with 1 ml PBS/Tween-80 (0.05%), and the 
bound proteins were dissolved in Laemmli's gel sample buffer. The samples 
were analyzed by discontinuous SDS-PAGE. 
Figure 1. Effect of TGFI3  on the proteolytic activity of A549 cells. 
The cells were cultivated in plastic Linbro wells. Upon confluency, 
2-3 d later, the cultures were changed to serum-free medium 199 
for 24 h. New medium supplemented with TGFI3  (5 ng/ml) was then 
added.  At different times, the media were collected (duplicates at 
each point) and analyzed by caseinolysis assays (see Materials and 
Methods). The values are plotted as Ploug units (PU/ml) by com- 
parison with a serial dilution of urokinase standard. (Inset) Results 
of the caseinolysis assays of the 24-, 36-, and 48-h time points; (up- 
per line) TGFI3;  (lower line) control. 
lmmunoprecipitation Analyses 
Rabbit antibodies against endothelial-type PA  inhibitor (PAl-l) were ob- 
tained from Dr. D. J. Loskutoff (Department of Immunology, Scripps Insti- 
tute and Research Foundation, La Jolla, CA). Human urokinase was immu- 
noprecipitated using  specific rabbit anti-u-PA lgG  antibodies (14). The 
immunoprecipitates were separated using protein A-Sepharose as previ- 
ously described (26),  followed by SDS-PAGE analysis, and fluorography. 
SDS-PAGE 
PAGE in the presence of SDS was performed according to Laemmli (25), 
using vertical slab gels. The samples were run nonreduced or reduced with 
10 % 2-mercaptoethanol in Laemmli's sample buffer. Radioactive molecular 
weight markers were purchased from Amersham International. After elec- 
trophoresis the gels were treated with Amplify (Amersham International) 
before drying for fluorography or processed for zymography assays (see 
below). 
Caseinolysis in Agarose Assays 
The assays for the demonstration of the total PA activity were performed 
using agarose plates containing plasminogen and casein as described in de- 
tail (45). Plasminogen, when activated by PA present in the medium sample, 
degrades casein and forms a clear disk of  caseinolysis in the gel proportional 
to the PA activity of  the sample and time of  diffusion. Human urokinase was 
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of medium (50 ttl) were analyzed in an 8%  SDS-PAGE under nonreducing conditions, followed by zymography assay (see Materials and 
Methods).  A casein-containing agarose gel was then placed onto the polyacrylamide gel. The gel was incubated at 37~  for 8 h and pho- 
tographed under indirect illumination. Note the increase of both u-PA and higher molecular mass complexes (Mr  100,000;  upper arrow) 
in the media of TGFl$-treated cultures. The incubation times of the cultures are shown. (B) Reverse zymographic detection of PAl activity. 
Medium aliquots (50 ttl) were analyzed for the presence of PA inhibitors by reverse zymography (see Materials and Methods). The samples 
were analyzed under reducing conditions in an 8% SDS-PAGE, known to inactivate u-PA. Note the increase of PAls in the medium from 
TGFI3-treated cultures (indicated in the figure). Incubation times of the cultures were (1) 24,  (2)  36,  (3) 48 h. 
used as a standard, and PA activity was plotted in Ploug units (from 50 to 
0.05 PU/ml).  Plates without added plasminogen were included to control 
for non-PA proteolysis. 
Zymography Assays 
Zymograpby and reverse zymography assays (13, 17) were used to demon- 
strate the migration of  either PAs or the PA inhibitors. To observe the molec- 
ular forms of PA activity the nonreduced medium samples were first sub- 
jected to electrophoresis  in  NaDodSO4-polyacrylamide gels.  NaDOdSO4 
was removed by extensive washing (200 ml, three times, 4 h) with PBS/Tri- 
ton X-100 (2.5%) followed by caseinolysis overlay assay as described earlier 
(27, 47). To observe the inhibitors (reverse zymography), the samples were 
reduced with 2-mercaptoethanol and analyzed in gels. This treatment inacti- 
vates PAs but does not affect PAI-I that does not contain disulfide bridges 
(see reference 6). The gels were finally incubated in 200 ml of PBS/Triton 
X-100 (2.5%)  containing 0.5 IU/ml urokinase at 22~  for 30 min (27). A 
casein-agarose  gel containing plasminogen was then placed on the poly- 
acrylamide  gel and the inhibition of caseinolysis was observed. 
RNA Isolation and Northern Blot Analysis 
Cytoplasmic poly(A+)-containing  RNA was prepared by previously pub- 
lished procedures.  Confluent cultures of cells were washed under serum- 
free  conditions  for 4-18  h,  and  exposed  to TGF[3 (5  ng/ml),  epidermal 
growth factor (5 ng/ml), or cycloheximide (1.5 I~g/ml)  for time periods de- 
scribed above. At the termination of the incubation the cells were lysed with 
lysing buffer (0.14 M NaCI, 0.002 M EDTA in 0.01 M Tris-HCl buffer, pH 
Z4), containing 1% SDS. The poly(A+)-containing  RNA was purified by 
one cycle of oligo-dT cellulose chromatography. 
For Northern  analysis equivalent quantities of RNA, as determined  by 
OD2~2a0 and ethidium bromide staining, were subjected to electrophoresis 
in 1.2% agarose gels containing 2.2 M formaldehyde. Conditions for elec- 
trophoresis,  transfer to nitrocellulose,  and hybridization  at 43~  to nick- 
translated 32p-labeled human urokinase eDNA (57) were performed as de- 
scribed (20). 
Results 
Effects of TGF~ on the Proteolytic Activity 
ofA549 Lung Carcinoma Cells 
Confluent cultures were placed in serum-free medium  199 
for 24 h to assure quiescence and removal of residual serum 
factors. The medium was then replaced with fresh serum- 
free medium supplemented with TGFI3 (1-20 ng/ml) and the 
proteolytic activity of the medium samples determined after 
8 h by caseinolysis assays. It was found that TGFI3 stimulated 
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level of urokinase in A549 cell medium: time dependency of TGFI~ 
stimulation. Confluent cultures of A549 cells were labeled with 
[35S]methionine in the presence of TGFI3 (5 ng/ml) and aprotinin 
(200 U/ml) for the times shown. After labeling the media were 
clarified by centrifugation and radiolabeled urokinase precipitated 
with specific antibodies. The immunoprecipitates were analyzed by 
8 % SDS-PAGE followed by fluorography. Densitometric analysis 
of the proteins in the Mr 50,000 region showed that after 24-h in- 
cubation the  amount of radiolabeled urokinase  antigen was  in- 
creased over twofold (respective relative densitometric values for 
urokinase from controls: 1, 2, 3.7, and from TGFfi-treated  cultures: 
2.5, 4, 7.7). 
proteolytic activity in the cultures by enhancing PA activity 
with submaximal effect at the concentration of 5 ng/ml (data 
not shown). A time course study showed that a sixfold en- 
hancement of net PA activity over control is obtained after 
48 h (Fig.  1). After treatment with SDS (0.2%) to inactivate 
SDS-sensitive PA inhibitors (for example protease-nexin I) 
(31, 48), the difference was of the same magnitude (data not 
shown). Thus, TGFI3 induces a time- and dose-dependent in- 
crease in net PA activity in A549 cells. 
Zymographic Analysis of  PA Activity 
Medium samples from TGF~treated cells were analyzed by 
SDS-gel  electrophoresis to  visualize  the  molecules  con- 
tributing the PA activity (6,  17). Analysis of the caseinolysis 
overlay indicator gel showed a PA activity band in A549 cells 
that comigrates with u-PA marker (Mr 52,000). The TGFI~- 
dependent increase in u-PA (Fig. 2 a) agrees with the results 
of the caseinolysis assays (Fig.  1). A higher molecular mass 
form of PA activity ('~100 kD) was also observed in the sam- 
ples from TGFl3-treated cells (Fig. 2 a, arrow); this corre- 
sponds to previously described (5, 6) SDS-stable complexes 
between u-PA  and  PAI-1 (see also  26,  28).  The  fact that 
u-PA/PAI-1  complex shows enzymatic activity is probably 
due to the proteolytic degradation of PAId by u-PA (2, 38). 
Both the high  molecular mass  PA activity and  the active 
52-kD u-PA were increased in TGF~treated cells. No activ- 
ity band was observed in the absence of plasminogen (not 
shown). 
Reverse zymography assays of the unfractionated condi- 
tioned medium samples of the same experiment showed that 
a  PA-inhibitory activity was  demonstrable only in TGF~ 
treated cultures. The inhibitor migrated in gels just behind 
u-PA and was not easily demonstratable because of  high u-PA 
activity  (gel  not  shown).  However, when  analyzed under 
reducing  conditions  where  u-PA  activity  is  destroyed,  a 
time-dependent increase ofPA inh~ition in the PAI-1 region 
was clearly seen (Fig. 2 b). This result supports the conclu- 
sion in Fig. 2 a that the 100-kD band is a complex between 
u-PA  and  PAI.  Immunoprecipitation  experiments  showed 
that this inhibitor is in fact PAI-1 (see Fig. 4). 
Detection of Urokinase by Immunoprecipitation 
To study whether TGFI3 affects the synthesis of urokinase, 
immunoprecipitation with anti-u-PA antibodies of  the condi- 
tioned media of metabolically labeled A549 cells was per- 
formed. Confluent cultures of A549 cells were labeled with 
[35S]methionine  under  serum-free conditions  in  the  pres- 
ence of TGFI3 (5  ng/ml)  and aprotinin (100 IU/ml).  After 
different incubation times, the medium was collected and im- 
munoprecipitation analysis was  carried out from identical 
volumes using antibodies against human u-PA. Analysis of 
the autoradiograms of the immunoprecipitates by densito- 
metric  scanning  showed  that  TGF~treated cells  secreted 
about twofold more radiolabeled u-PA antigen than the con- 
trol indicating enhanced  synthesis and  secretion (Fig.  3). 
The  100-kD  complex was not recognized by anti-catalytic 
u-PA antibodies (Fig. 3), but was recognized by monoclonal 
antibodies against the A  chain of u-PA (data not shown). 
Effects of TGF~ on Plasminogen Activator 
Inhibitor Production 
We have previously shown that treatment of cultured cells 
with TGFI3 leads to enhanced production of PAI-1 in human 
fibroblastic (26) and sarcoma cells (28). The PAI-1 is known 
to bind to Con A-Sepharose and to migrate in SDS-poly- 
acrylamide gels as a  47,000-Mr  protein (26).  To study the 
effect of TGFI3 on PAl-1 synthesis, A549 cells were labeled 
for 18 h with [35S]methionine with or without TGFI3. Equiv- 
alent aliquots of the radiolabeled medium from A549 cells 
(and HT-1080 cells as a positive control; reference 28) were 
incubated with Con A-Sepharose and the bound polypep- 
tides eluted with Laemmli's sample buffer and analyzed by 
SDS-PAGE. Analysis of the gel fluorograms indicated that 
the intensity of a 47,000-Mr  protein was enhanced in sam- 
pies  from TGFI3-treated cultures  (Fig.  4).  In  addition,  a 
prominent 70,000-Mr protein was observed in the medium. 
The nature of the 70,000-Mr protein will be object of further 
studies. 
To analyze whether the A549  cell-derived radiolabeled 
47,000-Mr  protein was associated with PA-inhibitory activ- 
ity, a reverse zymography assay was performed. Con A-bind- 
ing proteins were analyzed in an 8 % SDS-polyacrylamide 
gel under reducing conditions which are known to inactivate 
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inhibitor level in A549 cell medi- 
um.  Confluent cultures of A549 
cells were labeled with [35S]me- 
thionine under serum-free condi- 
tions in the presence of TGFI5 (5 
ng/ml; -  or +) as shown. (Le~) 
The media were collected after an 
18-h labeling and  PAI-1 isolated 
from l-ml aliquots by binding to 
Con  A-Sepharose  followed  by 
SDS-PAGE analysis (see Materi- 
als and Methods).  HT-1080 cells 
were  used as  a  positive control 
(28).  A  fluorogram  of  an  8% 
SDS-PAGE  is  shown.  Note  the 
enhancement of a 47,000-Mr pro- 
tein (47, arrow) in samples from 
TGF~treated cells. (Center)  Re- 
verse zymographic analysis of  the 
respective A549 medium samples 
indicating activity of the 47,000- 
Mr protein (negative of the pho- 
tograph is shown). (Right) Immu- 
noprecipitation  analysis  of  the 
medium at 12 h using anti-PAI-I 
antibodies. Open arrow indicates 
the  position  of  70,000-Mr  pro- 
tein(s) based on markers. The po- 
sition of PAI-1 (47) is also shown. 
Figure 5. Northern blot analysis of urokinase mRNA in A549 cells and WI-38 human lung fibroblasts. The cells were grown as described 
in the Materials and Methods section with TGFI3 (5 ng/ml). At the times indicated poly(A  +) mRNA was isolated and analyzed by North- 
ern blotting using a human urokinase cDNA probe (see Materials and Methods). The relative amounts of mRNA were estimated from 
the autoradiograms using laser scanning densitometry. A, A549 lung carcinoma cells; B, WI-38 lung fibroblasts. (Insets) The results of 
the Northern blot analyses. The mobilities of the marker RNAs are shown on the left. 
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Figure 6. Regulation  of u-PA mRNA 
in A549 and WI-38 cells by TGFI3: 
dose  dependency. The cells  were 
treated with increasing concentra- 
tions of TGFI3 (indicated on the fig- 
ure) for 4, (A549) or 1 h (WI-38), 
followed by isolation of mRNA as 
described in Materials and Meth- 
ods. Northern hybridization analy- 
sis was carried out using the human 
urokinase  cDNA  probe,  and  the 
levels of mRNA were estimated by 
densitometric scanning. The values 
are expressed as relative units, and 
therefore  the  amounts  of mRNA 
are  not  comparable  between  the 
two cell lines. The designations of 
the cell lines are indicated. 
the presence or absence of TGFI3 for 5 h. Northern blot anal- 
ysis of  the respective mRNAs shows that cycloheximide itself 
is able to enhance the expression of urokinase and that the 
inhibition of protein synthesis does not prevent the effect of 
TGFI3 (Fig. 7). In WI-38 cells, cycloheximide also enhances 
the  expression of urokinase  mRNA,  but  its  effect is  an- 
tagonistic with TGFI3 (not shown). 
Discussion 
TGFI~ is a growth modulator, which can either stimulate or 
inhibit growth depending on the cell system used (35,  44, 
54). Its effects are mediated via specific cell surface receptors 
that are as ubiquitous as TGFI~ itself (11, 15, 33,  53).  Both 
monomeric  and  disulfide-bonded  multisubunit  receptor 
complexes have been found at the cell surfaces in chemical 
cross-linking studies (7, 33). Many of the diverse biological 
activities of TGFI3 may be indirect through stimulation, syn- 
protease nexin-I and PAs (6, 26). Reverse zymography indi- 
cated  that  the 47,000-M, polypeptide was  associated with 
PA-inhibitory activity (Fig. 4) in a way similar to the samples 
from WI-38 fibroblastic cells (26), suggesting that the inhibi- 
tor is PAI-1. To further identify the PAI activity in TGF~ 
stimulated cultures immunoprecipitation analysis using anti- 
PAI-1 antibodies was performed. A 47,000-M, protein was 
precipitated from the medium of TGF~treated cells as shown 
previously using WI-38 cells (26) (Fig. 4,  right lanes). 
Effect of TGF[3 on the Expression 
of the Urokinase Gene 
The previous data demonstrate that TGFI~ can increase both 
the activity and synthesis of PA in A549 cells (Figs. 1-3). We 
have previously demonstrated that TGFI~ decreases u-PA ac- 
tivity  in  WI-38  normal  human  fibroblasts  (26).  We  have 
therefore determined whether this difference in TGFI3 effect 
could be also visible at the level of urokinase mRNA  ac- 
cumulation. Cells were grown to confluency and treated with 
TGFI3 under serum-free conditions. Cytoplasmic poly(A§ - 
mRNA  was  isolated  and  Northern  hybridization analysis 
carried out using a human urokinase probe. In accordance 
with the data of Fig. 1, it was found that TGFI~ enhanced the 
level of  urokinase mRNA in A549 cells (Fig. 5 A). This u-PA 
mRNA increase is observed already at 20 min, peaks '~5 h 
after TGFI3 addition,  and  remains  unchanged for at least 
24 h (Fig. 5 A, scanning curve). A TGFI3 time-dependency 
study of the mRNAs from WI-38 cells showed an early in- 
crease of u-PA mRNA followed by a two- to threefold de- 
crease (Fig.  5 B). 
When the dose dependence of TGFfl induction was ana- 
lyzed in A549 and WI-38 cells with 4- and  1-h treatment 
times, respectively, a bell-shaped response was obtained not 
only with A549 cells but also with WI-38 cells (Fig. 6). The 
maximal induction was reached at ~1 ng/ml of TGFI3 in both 
cases. Obviously, TGFI3 increases the level of u-PA mRNA 
in both cells. However, in WI-38 cells it also triggers another 
mechanism that leads  to a  fast disappearance of the u-PA 
mRNA. 
To determine whether the induction of urokinase mRNA 
is a primary event not dependent on prior protein synthesis, 
A549 cells were treated with cycloheximide (1.5 Ixg/ml) in 
Figure 7.  Effect of cycloheximide and TGFI~ on u-PA mRNA in 
A549 cells. The cultures were incubated under serum-free condi- 
tions as described in Materials and Methods and treated with cyclo- 
heximide (1.5 ~tg/ml) in the presence of TGFI~ (5 ng/ml) for 5 h. 
The poly(A  §  mRNA was isolated and analyzed by Northern hy- 
bridization.  The relative amounts of the mRNA were estimated 
densitometrically from the autoradiogram. (I-q)  Control, untreated; 
($I]) TGFI3-treatment;  (l~l) cycloheximide; (1~) treatment with both 
TGFI3 and cycloheximide. Insert: The autoradiogram (samples in 
the respective order) with RNA markers (28S and 18S). 
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trix components (21). Here we have carried out a study on 
the effects of TGFI~ on the synthesis and activity of u-PA in 
A549 human lung carcinoma cells. 
In this paper we have shown that TGFI3 enhances the over- 
all fibrinolytic activity of A549 cells (Fig. 1). This is at vari- 
ance with what was observed with WI-38 fibroblasts (26, 
32).  We have analyzed the molecular nature of the effect of 
TGFI3 in A549 cells and have compared it with previously 
published (26) or new data (Figs. 5 and 6) from WI-38 cells. 
In A549 cells, the increase in plasminogen activator activity 
is due to an increase of u-PA synthesis as shown by immuno- 
precipitation experiments with metabolically labeled ceils. 
This is in turn due to an elevated level of u-PA mRNA; the 
mRNA increase becomes evident by 20 min after TGFI~ addi- 
tion. The effect of TGFI3 on u-PA mRNA does not require 
protein synthesis as it is not blocked by cycloheximide (Fig. 
7). In WI-38 cells, however,  the treatment with TGFI3 was 
reported to reduce the overall plasminogen activator activity 
(26) due to a decrease in plasminogen activator activity and 
to a strong increase in the production of PAI-1 (26). We have 
now extended this investigation and measured the levels of 
u-PA mRNA in TGFfi-treated WI-38 cells (Figs. 5 B and 7). 
In WI-38 cells the level of u-PA mRNA, while being still in- 
creased by cycloheximide treatment (as  in A549 cells),  is 
also increased by "I'GFI3  for short treatment times. However, 
this early increase is followed by a drastic decrease of u-PA 
mRNA level  (Fig. 5 B). Therefore, in WI-38 cells the net 
effect will be a decrease of u-PA mRNA and hence of u-PA 
synthesis. We interpret these results so that the primary effect 
of TGFI3 may be to increase u-PA mRNA level in both A549 
and WI-38 cells. In WI-38 cells, however, a second mecha- 
nism is triggered that induces a drastic reduction of the u-PA 
mRNA level. This mechanism may be acting at the level of 
mRNA half-life. However, further studies are required to un- 
derstand this point. 
While TGFI3 affects u-PA mRNA level in opposite direc- 
tions in A549 and WI-38 cells, its effect on PAI-1 is similar 
in the two types of cells.  In fact TGFI3 induces PAI-1 in 
A549 cells (Fig. 4),  an effect qualitatively similar to that 
reported for WI-38 cells (26, 32).  However, the production 
of PAI-1 mRNA in response to TGFI3 differs in these two cell 
types, being considerably less in A549 cells (24).  The final 
effect on the fibrinolytic activity of A549 cells is therefore 
different in the two cells;  TGFI3 causes a  net decrease in 
WI-38 cells, and a net increase in A549 cells. The latter is 
also evidenced by the increase in the u-PA/PAI-1 complex in 
TGF~treated A549 cells (see Fig. 2 a). 
It is interesting to note the opposing effect of TGFI3 on 
u-PA activity of cells of mesenchymal (decrease) and epithe- 
lial (increase) origin. TGFI3 has opposing effects also on the 
growth properties of these two cell lines (35, 44). The intrin- 
sic  complexity of the growth and pericellular proteolytic 
pathway prevents a meaningful correlation between cellular 
growth and proteolytic activity in these cell lines. Obviously, 
the combined action of different endogenous and exogenous 
growth factors, proteases and protease inhibitors may have 
divergent effects on different cells, the final result depending 
on a carefully controlled balance between them. In any case, 
since the effect of TGF[~ on u-PA mRNA has so far been stud- 
ied only in A549 and WI-38 cells, any generalization will 
have to  await for  further  studies  on  other  epithelial and 
mesenchymal cell lines. 
Growth-promoting  Factors  in the Regulation 
of  PA Activity 
Growth factors appear to play an important role in the regula- 
tion of the proteolytic activity of cultured cells (see refer- 
ences 9, 46). Various hormones and hormonelike substances 
can alter the secretion of both PAs and PAIs (1,  18, 36, 40, 
42). Exposure of suitable cell types in culture to physiologi- 
cal concentrations of steroids, vasopressin, calcitonin, relax- 
in, and other polypeptide hormones from pituitary glands 
have been shown to elevate  PA activity (see 9, 46).  A role 
for EGF and phorbol esters in the regulation of PA activity 
has been suggested in a number of studies (12, 18, 19, 29, 39, 
58).  An increase of u-PA mRNA was observed in cultured 
human carcinoma cells treated with biologically active phor- 
bol esters (52). The secretion of t-PA by cultured cells is also 
sensitive to effectors of cellular growth (26, 29, 39). Interest- 
ingly, TGFI3 appears to have divergent direct effects on the 
u-PA level in different cells even though being in both cases 
a  positive activator at the genetic level.  This system may 
prove of great interest in elucidating the effects of TGFI3 at 
the  genetic  level.  The  bell-shaped  form of the  dose-de- 
pendency curve suggests that alterations of TGFI3 concentra- 
tion may modify the u-PA responses in the microenviron- 
ment of the cells. Our results, however, cannot be explained 
on the basis of a different sensitivity of the two cells to TGFI3. 
In fact, induction of 13-actin and c-sis mRNA follows the 
same time and concentration dependence in A549 and WI-38 
cells (our unpublished results). 
As another aspect we have recently found evidence for pro- 
teolytic activation of latent form of TGF[~ (Lyons, R. M., J. 
Keski-Oja, and H. L. Moses, manuscript submitted for pub- 
lication). This might offer the cells a regulatory mechanism 
to control the proteolytic balance in their microenvironment. 
Growth Regulation and Extracellular Matrix 
Enhanced proteolytic activity may cause degradation of the 
pericellular structures (40) required for anchorage-indepen- 
dent growth. If the induction of pericellular matrix proteins 
(21) and a decrease in proteolytic activity due to production 
of PAI-1 (26) are essential features for the support of soft agar 
growth of nontumorigenic cells, TGFI3 might regulate an- 
chorage-independent growth by regulating the proteolytic 
activity of these cells (see 37). TGFI3 is, however, inhibitory 
for A549 and several other cell types in substratum-attached 
cultures, and other mechanisms must therefore be involved 
in monolayer growth inhibition. 
It is not yet established how different malignant cells re- 
spond to TGFI3 in the production of PAI-1. It has recently 
been shown that protease-nexin I and anti-u-PA antibodies 
decrease tumor cell-induced degradation of pericellular ma- 
trices (4, see reference 31). TGF[~-induced extracellular ma- 
trix-associated PAI-1 is expected to have a similar effect (28); 
thus TGFI3 might regulate pericellular proteolysis through its 
action on PAI-1. A positive correlation between optimal pro- 
teolytic activity and anchorage-independent growth could be 
an essential part of the action of TGFI3. TGFI3 might attain 
this goal by changing the balance between PAs and PAIs. An 
alteration in such a  response might indicate that the cells 
have  changed in  their  responsiveness  to  TGF~I (see  37). 
Identification of novel inhibitory and stimulatory signals that 
operate between proteolytic enzymes and growth factors may 
Keski-Oja et al. Regulation of u-PA Activity by TGF~  457 reveal  new  regulatory  routes  of  invasive  and  malignant 
growth. 
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